MedKoo Cat#: 461389 | Name: Robenacoxib
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID) with high selectivity for the cyclo-oxygenase-2 enzyme.

Chemical Structure

Robenacoxib
Robenacoxib
CAS#220991-32-2

Theoretical Analysis

MedKoo Cat#: 461389

Name: Robenacoxib

CAS#: 220991-32-2

Chemical Formula: C16H13F4NO2

Exact Mass: 327.0882

Molecular Weight: 327.27

Elemental Analysis: C, 58.72; H, 4.00; F, 23.22; N, 4.28; O, 9.78

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
25mg USD 550.00 2 Weeks
50mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Robenacoxib; Onsior;
IUPAC/Chemical Name
2-(5-ethyl-2-((2,3,5,6-tetrafluorophenyl)amino)phenyl)acetic acid
InChi Key
ZEXGDYFACFXQPF-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13F4NO2/c1-2-8-3-4-12(9(5-8)6-13(22)23)21-16-14(19)10(17)7-11(18)15(16)20/h3-5,7,21H,2,6H2,1H3,(H,22,23)
SMILES Code
O=C(O)CC1=CC(CC)=CC=C1NC2=C(F)C(F)=CC(F)=C2F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 327.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Speranza C, Schmid V, Giraudel JM, Seewald W, King JN. Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial. BMC Vet Res. 2015 Mar 26;11:79. doi: 10.1186/s12917-015-0391-z. PubMed PMID: 25880535; PubMed Central PMCID: PMC4379761. 2: Szweda M, Szarek J, Dublan K, Męcik-Kronenberg T, Kiełbowicz Z, Bigoszewski M. Effect of mucoprotective plant-derived therapies on damage to colonic mucosa caused by carprofen and robenacoxib administered to healthy dogs for 21 days. Vet Q. 2014;34(4):185-93. doi: 10.1080/01652176.2014.968939. Epub 2014 Oct 20. PubMed PMID: 25330194. 3: King JN, Hotz R, Reagan EL, Roth DR, Seewald W, Lees P. Safety of oral robenacoxib in the cat. J Vet Pharmacol Ther. 2012 Jun;35(3):290-300. doi: 10.1111/j.1365-2885.2011.01320.x. Epub 2011 Jul 8. PubMed PMID: 21736587. 4: Szweda M, Szarek J, Lew M, Szarek-Bęska A, Gulda D. Can liquorice extract and herbal solution prevent colonic mucosa damage caused by robenacoxib in dogs? Pol J Vet Sci. 2015;18(4):793-8. doi: 10.1515/pjvs-2015-0103. PubMed PMID: 26812822. 5: Pelligand L, King JN, Hormazabal V, Toutain PL, Elliott J, Lees P. Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. J Vet Pharmacol Ther. 2014 Aug;37(4):354-66. doi: 10.1111/jvp.12107. Epub 2014 Mar 15. PubMed PMID: 24628410. 6: Tamura J, Itami T, Ishizuka T, Fukui S, Ooyama N, Miyoshi K, Sano T, Yamashita K. Sparing effect of robenacoxib on the minimum alveolar concentration for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs. J Vet Med Sci. 2014 Jan;76(1):113-7. Epub 2013 Sep 4. PubMed PMID: 24004933; PubMed Central PMCID: PMC3979944. 7: Gruet P, Seewald W, King JN. Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial. BMC Vet Res. 2013 May 2;9:92. doi: 10.1186/1746-6148-9-92. PubMed PMID: 23638669; PubMed Central PMCID: PMC3655053. 8: King JN, Jung M, Maurer MP, Schmid VB, Seewald W, Lees P. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats. Am J Vet Res. 2013 Mar;74(3):465-72. doi: 10.2460/ajvr.74.3.465. PubMed PMID: 23438125. 9: King JN, Panteri A, Graille M, Seewald W, Friton G, Desevaux C. Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats. BMC Vet Res. 2016 Jun 23;12(1):124. doi: 10.1186/s12917-016-0734-4. PubMed PMID: 27338786; PubMed Central PMCID: PMC4917992. 10: Pelligand L, King JN, Toutain PL, Elliott J, Lees P. Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. J Vet Pharmacol Ther. 2012 Feb;35(1):19-32. doi: 10.1111/j.1365-2885.2011.01288.x. Epub 2011 Jul 18. PubMed PMID: 21767277. 11: Reymond N, Speranza C, Gruet P, Seewald W, King JN. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J Vet Pharmacol Ther. 2012 Apr;35(2):175-83. doi: 10.1111/j.1365-2885.2011.01297.x. Epub 2011 Apr 12. PubMed PMID: 21480932. 12: Staffieri F, Centonze P, Gigante G, De Pietro L, Crovace A. Comparison of the analgesic effects of robenacoxib, buprenorphine and their combination in cats after ovariohysterectomy. Vet J. 2013 Aug;197(2):363-7. doi: 10.1016/j.tvjl.2013.01.018. Epub 2013 Feb 21. PubMed PMID: 23434263. 13: Edamura K, King JN, Seewald W, Sakakibara N, Okumura M. Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial. J Vet Med Sci. 2012 Sep;74(9):1121-31. Epub 2012 May 17. PubMed PMID: 22673598. 14: King S, Roberts ES, King JN. Evaluation of injectable robenacoxib for the treatment of post-operative pain in cats: results of a randomized, masked, placebo-controlled clinical trial. BMC Vet Res. 2016 Sep 29;12(1):215. PubMed PMID: 27686251; PubMed Central PMCID: PMC5041542. 15: Kamata M, King JN, Seewald W, Sakakibara N, Yamashita K, Nishimura R. Comparison of injectable robenacoxib versus meloxicam for peri-operative use in cats: results of a randomised clinical trial. Vet J. 2012 Jul;193(1):114-8. doi: 10.1016/j.tvjl.2011.11.026. Epub 2012 Jan 9. PubMed PMID: 22227226. 16: Bennett D, Eckersall PD, Waterston M, Marchetti V, Rota A, McCulloch E, Sbrana S. The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis. BMC Vet Res. 2013 Mar 1;9:42. doi: 10.1186/1746-6148-9-42. PubMed PMID: 23452411; PubMed Central PMCID: PMC3610148. 17: Sano T, King JN, Seewald W, Sakakibara N, Okumura M. Comparison of oral robenacoxib and ketoprofen for the treatment of acute pain and inflammation associated with musculoskeletal disorders in cats: a randomised clinical trial. Vet J. 2012 Aug;193(2):397-403. doi: 10.1016/j.tvjl.2012.02.008. Epub 2012 Mar 18. PubMed PMID: 22430026. 18: Gruet P, Seewald W, King JN. Evaluation of subcutaneous and oral administration of robenacoxib and meloxicam for the treatment of acute pain and inflammation associated with orthopedic surgery in dogs. Am J Vet Res. 2011 Feb;72(2):184-93. doi: 10.2460/ajvr.72.2.184. PubMed PMID: 21281192. 19: Fink M, Letellier I, Peyrou M, Mochel JP, Jung M, King JN, Gruet P, Giraudel JM. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis. Res Vet Sci. 2013 Oct;95(2):580-7. doi: 10.1016/j.rvsc.2013.04.021. Epub 2013 May 31. PubMed PMID: 23726662. 20: King JN, Arnaud JP, Goldenthal EI, Gruet P, Jung M, Seewald W, Lees P. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2. J Vet Pharmacol Ther. 2011 Jun;34(3):298-311. doi: 10.1111/j.1365-2885.2010.01209.x. PubMed PMID: 21492194.